Thymogen (L-Glu–L-Trp)
Synthetic immunomodulatory dipeptide (L-glutamyl–L-tryptophan) · Pre-filled pen
Thymogen is a synthetic dipeptide (L-glutamyl–L-tryptophan) designed as a functional mimic of thymic peptide signalling. It is studied for effects on T-lymphocyte maturation and normalisation of immune-cell balance, aiming to regulate rather than indiscriminately amplify immune responses. Most published evaluation comes from a limited and largely regional body of literature.
Studied use areas
- Studied for supporting T-lymphocyte differentiation signalling
- Explored for normalising immune-cell ratio markers
- Investigated as an immune-modulating adjunct in research settings
- Examined where balanced, non-indiscriminate immune activation is the endpoint
Safety & status
- Investigational; human evidence is limited and largely regional and has not been evaluated by the EMA or MHRA
- May be unsuitable for people with autoimmune disease or those taking immunosuppressive therapy
- Long-term safety is not established, so physician supervision is required
⚕ Clinical note: This is educational information, not medical advice. Thymogen is an investigational immunomodulator whose human evidence is limited, so any effect described here is exploratory rather than promised. It is not a substitute for proven care and should only be used under qualified physician supervision.
Evidence: Grade C — investigational; human evidence is limited and largely regional · References: peer-reviewed immunopharmacology literature on thymic dipeptides; regional clinical reports on synthetic immunomodulatory peptides; reviews of thymic-peptide analogues
